MYELOPROLIFERATIVE NEOPLASMS
Clinical trials for MYELOPROLIFERATIVE NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new MYELOPROLIFERATIVE NEOPLASMS trials appear
Sign up with your email to follow new studies for MYELOPROLIFERATIVE NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to tame rare blood cancers in early trial
Disease control Recruiting nowThis study tests an experimental daily pill, JBI-802, in about 30 adults with certain blood cancers (MPN or MDS/MPN) that cause too many platelets. The goal is to check safety and see if the drug can lower platelet counts and shrink the cancer. Participants take the pill for up t…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Jubilant Therapeutics Inc. • Aim: Disease control
Last updated Jun 17, 2026 02:43 UTC
-
New drug combo targets rare blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new drug, INCA033989, given alone or with another drug (ruxolitinib) in 225 adults with myeloproliferative neoplasms, a group of rare blood cancers. The main goals are to check safety, find the best dose, and see how well the drug works. Participant…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 16, 2026 12:52 UTC
-
New combo therapy targets tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs, ivosidenib and ruxolitinib, in people with advanced blood cancers (MPNs) that have an IDH1 mutation. The main goal is to find the safest dose and see if the combo helps control the disease. About 18 adults will take part.
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
New drug combo aims to control rare blood cancers
Disease control Recruiting nowThis early-stage trial tests a new drug, INCA033989, given alone or with another drug (ruxolitinib) in about 290 adults with myeloproliferative neoplasms, a group of blood cancers. The main goals are to check safety, find the best dose, and see if it helps control the disease. Pa…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
New drug trial aims to tame rare blood cancers
Disease control Recruiting nowThis early-stage study tests a new drug, INCA035784, in 120 adults with certain blood cancers (myeloproliferative neoplasms). The main goal is to check safety and find the right dose. Participants must have specific genetic mutations and have tried other treatments before.
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 11, 2026 12:08 UTC
-
New hope for rare blood cancers? early trial begins
Disease control Recruiting nowThis early-phase study tests a new drug called INCB160058 in adults with myeloproliferative neoplasms, a group of rare blood cancers. The main goal is to check the drug's safety and how the body processes it. About 186 participants will receive the drug to find the right dose and…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 09, 2026 12:08 UTC
-
New drug INCA036978 enters human testing for rare blood cancers
Disease control Recruiting nowThis early-stage study tests an experimental drug, INCA036978, in about 218 adults with myeloproliferative neoplasms (a group of blood cancers). The main goal is to check the drug's safety and find the best dose, either alone or with standard treatment. Participants must have a l…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 08, 2026 13:12 UTC
-
Rare blood cancer in kids: new registry aims to unlock secrets
Knowledge-focused Recruiting nowThis study creates a nationwide registry in Germany for children and teens diagnosed with myeloproliferative neoplasms (MPNs), a rare group of blood cancers. Researchers will collect medical information and blood samples from up to 500 participants to learn how the disease behave…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Jun 17, 2026 02:42 UTC
-
New drug metabolism study launches for stubborn blood cancers
Knowledge-focused Recruiting nowThis study looks at how the body absorbs, breaks down, and gets rid of an experimental drug called DSP-5336. It involves 8 adults with advanced blood cancers (like leukemia or myeloma) that no longer respond to standard treatments. Participants take a single radioactive-labeled p…
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Phase: PHASE1 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Knowledge-focused
Last updated Jun 12, 2026 12:07 UTC
-
5,000 patients join Long-Term study to unlock mysteries of rare blood cancers
Knowledge-focused Recruiting nowThis study is a long-term observation of 5,000 adults with myeloproliferative neoplasms (MPNs), a group of rare blood cancers. Researchers will collect health records, insurance data, and patient surveys over at least five years to track symptoms, treatments, and how the disease …
Matched conditions: MYELOPROLIFERATIVE NEOPLASMS
Sponsor: MPN Research Foundation • Aim: Knowledge-focused
Last updated Jun 08, 2026 13:04 UTC